Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors
“Kristine is an internationally recognized expert in the field of cognitive aging, neurodegeneration and dementia,” said
Dr. Yaffe has received numerous awards for her groundbreaking contributions to the field including the
"What excites me most about the opportunity to join
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South
Source: Alector, Inc.